<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Because of its broad-spectrum antiviral activity, nitazoxanide is being studied in clinical trials, including randomized controlled trials, to control influenza and other acute respiratory infections, although the results are either not encouraging or unavailable. However, the 
 <italic>inÂ vitro</italic> activity of nitazoxanide against SARS-CoV-2 is encouraging, it is clear that more data are needed to determine its role in the management of COVID-19 [
 <xref rid="bib55" ref-type="bibr">55</xref>].
</p>
